FFS
IBRX icon

Founders Financial Securities’s ImmunityBio IBRX Stock Holding History

Founders Financial Securities’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14,502
Closed -$175K – 185
2020
Q2 		$175K Buy
+14,502
New +$81.9K 0.06% 162

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Founders Financial Securities's IBRX Position: Q3 2020 in Review

Founders Financial Securities sold out of ImmunityBio (IBRX) in Q3 2020, closing a stake of 14,502 shares — an estimated $175K sold.

Founders Financial Securities first reported a position in IBRX in Q2 2020 and held it in 1 quarter. The position peaked at $175K in Q2 2020. 95 funds tracked by Wall St. Rank hold IBRX as of Q3 2020.

  • Founders Financial Securities reported no remaining ImmunityBio position as of Q3 2020 after selling out during the quarter.
  • Founders Financial Securities sold 14,502 ImmunityBio shares in Q3 2020, an estimated $175K.
  • Founders Financial Securities first reported a position in ImmunityBio in Q2 2020 and held it in 1 quarter.
  • Founders Financial Securities's ImmunityBio position peaked at $175K in Q2 2020.
  • 95 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2020.

Based on Founders Financial Securities's 13F filing for Q3 2020, filed 16 Nov 2020.